Souders Financial Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $443K | Sell |
1,359
-434
| -24% | -$142K | 0.06% | 140 |
|
|
2025
Q1 | $484K | Sell |
1,793
-947
| -35% | -$256K | 0.07% | 131 |
|
|
2024
Q4 | $645K | Sell |
2,740
-613
| -18% | -$144K | 0.09% | 118 |
|
|
2024
Q3 | $922K | Sell |
3,353
-159
| -5% | -$43.7K | 0.13% | 106 |
|
|
2024
Q2 | $853K | Buy |
3,512
+36
| +1% | +$8.75K | 0.13% | 102 |
|
|
2024
Q1 | $519K | Buy |
3,476
+529
| +18% | +$79.1K | 0.08% | 119 |
|
|
2023
Q4 | $564K | Buy |
2,947
+255
| +9% | +$48.8K | 0.1% | 112 |
|
|
2023
Q3 | $477K | Buy |
2,692
+39
| +1% | +$6.91K | 0.09% | 118 |
|
|
2023
Q2 | $504K | Buy |
2,653
+417
| +19% | +$79.2K | 0.1% | 117 |
|
|
2023
Q1 | $448K | Buy |
2,236
+57
| +3% | +$11.4K | 0.1% | 116 |
|
|
2022
Q4 | $518K | Buy |
2,179
+512
| +31% | +$122K | 0.12% | 109 |
|
|
2022
Q3 | $334K | Buy |
+1,667
| New | +$334K | 0.09% | 126 |
|